A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

Lupin launches Ipratropium Bromide Nasal Solution in the US market; eyes expanding complex generics pipeline to over 200 ...

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

Mumbai: Global pharma major Lupin Limited has launched Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in ...

According to Future Market Insights (FMI), the nasal packing devices market will hit USD 209.2 million by the end of 2025 and ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) is among the best growth stocks to invest in for the next 5 years. Analysts at H.C ...

Probation officials said youths and staff members were hospitalized after a 'suspected overdose and possible exposure to an ...

With allergy-related symptoms and conditions on the rise amongst children, an increasing number of parents and caregivers are ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

MomMed, a trusted maternal and family wellness brand, today announced a strategic partnership with nasal care innovator ...